Investments

A Secret About Drug Development

People watching pharma companies and the drug development process (this includes investors/VCs, academia and the general public) from the outside will seldom think about this unmet need. The Problem If you’re a scientist, you don’t participate in the upside but you participate a lot in the downside in the case a drug fails to make it past trials and onto the market.. This isn’t exactly a secret (see interview: Vivek Ramaswamy, Roivant Sciences CEO), but is something casual biology enthusiasts or scientists in academia may not appreciate.

A Secret About Drug Development

People watching pharma companies and the drug development process (this includes investors/VCs, academia and the general public) from the outside will seldom think about this unmet need. The Problem If you’re a scientist, you don’t participate in the upside but you participate a lot in the downside in the case a drug fails to make it past trials and onto the market.. This isn’t exactly a secret (see interview: Vivek Ramaswamy, Roivant Sciences CEO), but is something casual biology enthusiasts or scientists in academia may not appreciate.

Bottos (BTO): the best AI crypto of 2018

A large problem with artificial intelligence today lies in the lack of reliable data sources. To be successful, many companies have had to rely on having exclusive access to data. This works fine for large companies with clout like Google and Facebook, but puts small and medium size businesses at a huge disadvantage. Bottos is solving this problem with a blockchain solution for data sharing as well as AI model sharing.